Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastrointestinal Cancer
Beijing GoBroad Hospital
Beijing GoBroad Hospital
Second Affiliated Hospital, School of Medicine, Zhejiang University
Henry Ford Health System
University of Nebraska
Fox Chase Cancer Center
Indiana University
NYU Langone Health
University of Utah
Peking University
The Netherlands Cancer Institute
University of Rochester
University of Chicago
Washington University School of Medicine
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Virginia Commonwealth University
Institut du Cancer de Montpellier - Val d'Aurelle
University of Illinois at Chicago
Jules Bordet Institute
M.D. Anderson Cancer Center
University of Nottingham
Hallym University Medical Center
Technical University of Munich
Dana-Farber Cancer Institute
Shandong University
M.D. Anderson Cancer Center